EphA2 expression is associated with aggressive features in ovarian carcinoma.
about
Role of microRNA-26b in glioma development and its mediated regulation on EphA2An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cellsSoluble monomeric EphrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptorEphs and ephrins in cancer: ephrin-A1 signallingEphs and Ephrins in malignant gliomasPreclinical and clinical development of siRNA-based therapeuticsThe ZNF304-integrin axis protects against anoikis in cancerThe ephrin receptor tyrosine kinase A2 is a cellular receptor for Kaposi's sarcoma–associated herpesvirusPleural mesothelial cells in pleural and lung diseasesDevelopment of nanoscale approaches for ovarian cancer therapeutics and diagnosticsIncreased expression of EphA7 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients.Chemosensitization of cancer cells by siRNA using targeted nanogel delivery.High expression and frequently humoral immune response of melanoma-associated antigen D4 in gliomaHematogenous metastasis of ovarian cancer: rethinking mode of spread.Overexpression of MAGE-D4 in colorectal cancer is a potentially prognostic biomarker and immunotherapy targetPrognostic biomarkers in ovarian cancer.Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors.A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo.Emerging strategies for EphA2 receptor targeting for cancer therapeutics.Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancerEphA4 is a prognostic factor in gastric cancer.Anti-EphA2 antibodies decrease EphA2 protein levels in murine CT26 colorectal and human MDA-231 breast tumors but do not inhibit tumor growthEphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer.Hsp90 is an essential regulator of EphA2 receptor stability and signaling: implications for cancer cell migration and metastasis.Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches.Microenvironment and pathogenesis of epithelial ovarian cancerInhibitors of Glioma Growth that Reveal the Tumour to the Immune System.Sustained small interfering RNA delivery by mesoporous silicon particlesExpression of EphA2 and EphrinA-1 in vulvar carcinomas and its relation to prognosisEphA2 as a target for ovarian cancer therapy.Expression of EphA2 protein is positively associated with age, tumor size and Fuhrman nuclear grade in clear cell renal cell carcinomasEphA2 as a promoter of melanoma tumorigenicityBiological significance of HORMA domain containing protein 1 (HORMAD1) in epithelial ovarian carcinomaEph-A2 and Eph-A4 expression in human benign and malignant thyroid lesions: an immunohistochemical studyExpressions of EphA2 and EphrinA-1 in early squamous cell cervical carcinomas and their relation to prognosis.Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery.The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting.Moving beyond VEGF for anti-angiogenesis strategies in gynecologic cancerPathophysiology of the pleura.Ovarian cancer biomarkers: a focus on genomic and proteomic findings.
P2860
Q21135751-4B7B822C-E5A0-426B-B8C2-DE480066BD3BQ24302462-0942BF5D-E1B6-45DF-9FAF-17C1C9F05C1BQ24313139-014AAB04-5DFA-4480-A1A0-8F21CE896E8AQ26864889-FD90BC28-7C44-44EA-9D87-91E638668432Q27015780-C8244A44-9D19-4DBD-A68C-803F02F809D2Q28085290-7647DDA3-9FDA-4399-BB05-4DCB45956600Q28115264-1DDDD374-4E85-4F19-B5BE-6F179CCDD490Q28267511-E8A92985-BD9D-4403-8823-BB182FDC80E0Q28396403-D31412E4-3E10-4298-A68F-CDC3595DC49FQ30421664-BD153432-C08B-4742-9A23-36132A6963A0Q33325737-8DFEE4E9-39C7-405B-8F3E-6F80773EC391Q33523195-D492C471-6F3B-4277-9377-B8666357A3A3Q33802891-ACF3A671-3124-4945-8E1C-B58B93513CF2Q33908024-EBAC3C6C-ADC3-4B4E-90EE-0C46BECC5038Q34029028-CD9FC257-18BA-472A-BC1A-57B97B6BCA32Q34086636-BA28039B-C0BB-40AB-A0A5-8E70D0B4EC5BQ34257256-3724CACD-61C2-4F4F-AB1D-248B2133A4CFQ34390813-CAE5848D-41A1-453A-AA2A-09BF189C38C9Q34469271-EBD06C1D-40E1-47DA-8CA6-2AD4179061FBQ34616549-B619542B-4CAF-49DA-BD7C-291F2FDA4C56Q34759687-BC1DF085-5945-4FB9-9C3C-42D414760E3AQ35060278-6077D828-9440-418A-9A0E-E391EB6BC50DQ35114341-3796E57F-6815-48A3-9430-290DAE1F5859Q35161906-02507CD4-47C4-4C2B-B9FB-3638ADB6A715Q35205410-802D8936-6B3A-4E7A-98D2-765A26AA8FFAQ35419057-B272C8E6-9B9F-4A08-B5E4-D802C3DF16F6Q35440540-575E8106-1E79-4724-9D76-5DB5BAF33054Q35456065-994BAC0A-C6F9-4689-85F6-F792966DEB48Q36054843-61F8BFFE-A17D-49BE-B54A-2CE7F5F36AD4Q36318535-3AAF12F8-BE42-4A5E-831D-691CB623BB54Q36375472-B0D02425-DB5D-4F0C-B7C6-11EEDBFA203BQ36379022-06F560BB-6A2F-4209-AEF5-7434A262EF3AQ36400401-854BE2DB-43D7-41F9-B3D1-68B43397FB89Q36576644-7F806D67-767E-470B-8C53-54EB18917368Q36713605-CA3D7691-53D4-4ACD-8607-83F0470CFA3CQ36745501-DC040EE0-D361-4667-81E5-E6326E3EC04DQ36950556-6AEA7120-706E-49D9-8074-A8955B8137A1Q37086837-215B5D38-CC6A-46A3-9072-291A7A60F7FBQ37106987-9E9A88CB-9AA2-4EB8-9D26-C7440F9E1D68Q37119992-02FAA6AB-5EE0-4DA1-B270-425964069C67
P2860
EphA2 expression is associated with aggressive features in ovarian carcinoma.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
EphA2 expression is associated with aggressive features in ovarian carcinoma.
@en
type
label
EphA2 expression is associated with aggressive features in ovarian carcinoma.
@en
prefLabel
EphA2 expression is associated with aggressive features in ovarian carcinoma.
@en
P2093
P1476
EphA2 expression is associated with aggressive features in ovarian carcinoma.
@en
P2093
Angela Thornton
Anil K Sood
Charles N Landen
Joseph Celestino
Mavis S Fletcher
Michael Deavers
Peter A Kiener
Premal H Thaker
P304
P356
10.1158/1078-0432.CCR-03-0589
P407
P577
2004-08-01T00:00:00Z